Oncolytics Historical Balance Sheet

ONC Stock

CAD 1.32 0.06 4.35%

Trend analysis of Oncolytics Biotech balance sheet accounts such as Total Stockholder Equity of 17.8 M provides information on Oncolytics Biotech's total assets, liabilities, and equity, which is the actual value of Oncolytics Biotech to its prevalent stockholders. By breaking down trends over time using Oncolytics Biotech balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Oncolytics Biotech latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Oncolytics Biotech is a good buy for the upcoming year.

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide.

About Oncolytics Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Oncolytics Biotech at a specified time, usually calculated after every quarter, six months, or one year. Oncolytics Biotech Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Oncolytics Biotech and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Oncolytics currently owns. An asset can also be divided into two categories, current and non-current.

Oncolytics Biotech Balance Sheet Chart

At this time, Oncolytics Biotech's Cash And Equivalents is very stable compared to the past year.

Total Assets Short Long Term Debt Total Total Current Liabilities Property Plant And Equipment Net Net Tangible Assets

Add Fundamental

Total Assets

Total assets refers to the total amount of Oncolytics Biotech assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Oncolytics Biotech books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Oncolytics Biotech balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Oncolytics Biotech are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Most accounts from Oncolytics Biotech's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Oncolytics Biotech current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide.At this time, Oncolytics Biotech's Cash And Equivalents is very stable compared to the past year.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	654.8K	373K	423K	301.2K
Total Assets	45.9M	37.3M	38.8M	30.5M

Short Long Term Debt Total Total Assets

Oncolytics Biotech balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Non Currrent Assets Other	Short Term Investments	Short Term Debt	Other Assets	Other Current Liab	Common Stock
Total Assets		0.3	0.01	0.9	0.74	-0.84	-0.62	-0.12	0.84	-0.13	0.98	-0.15	0.7	0.46	0.73	0.63	0.32	0.65	1.0	-0.48	0.45	-0.06	-0.49	-0.03	0.04	0.65
Short Long Term Debt Total	0.3		0.37	0.24	0.58	-0.33	-0.29	0.42	0.46	-0.7	0.33	0.23	-0.12	-0.03	-0.1	0.23	0.32	0.05	0.36	-0.72	0.24	-0.5	-0.67	-0.74	-0.17	0.19
Total Current Liabilities	0.01	0.37		-0.3	0.29	0.02	-0.15	0.55	0.0	-0.39	-0.03	0.34	-0.11	0.09	-0.03	0.21	0.71	0.11	0.03	-0.42	0.23	-0.15	-0.41	-0.32	0.6	-0.01
Total Stockholder Equity	0.9	0.24	-0.3		0.51	-0.78	-0.33	-0.07	0.82	-0.04	0.94	-0.33	0.48	0.12	0.47	0.34	-0.1	0.41	0.9	-0.3	0.24	-0.15	-0.25	-0.03	-0.23	0.42
Property Plant And Equipment Net	0.74	0.58	0.29	0.51		-0.58	-0.75	-0.17	0.63	-0.23	0.7	0.04	0.59	0.59	0.62	0.71	0.64	0.63	0.76	-0.61	0.69	-0.05	-0.63	-0.29	0.16	0.77
Net Debt	-0.84	-0.33	0.02	-0.78	-0.58		0.46	0.09	-0.95	0.35	-0.86	0.26	-0.54	-0.31	-0.55	-0.47	-0.13	-0.68	-0.84	0.44	-0.06	0.29	0.41	-0.12	-0.03	-0.41
Retained Earnings	-0.62	-0.29	-0.15	-0.33	-0.75	0.46		0.34	-0.39	0.35	-0.55	-0.11	-0.84	-0.81	-0.84	-0.98	-0.6	-0.8	-0.62	0.7	-0.42	-0.05	0.79	0.01	0.01	-0.93
Accounts Payable	-0.12	0.42	0.55	-0.07	-0.17	0.09	0.34		-0.03	-0.48	-0.04	0.04	-0.55	-0.63	-0.55	-0.24	-0.05	-0.35	-0.08	-0.33	-0.22	-0.51	-0.2	-0.49	-0.09	-0.52
Cash	0.84	0.46	0.0	0.82	0.63	-0.95	-0.39	-0.03		-0.34	0.87	-0.22	0.41	0.23	0.43	0.36	0.18	0.52	0.86	-0.43	0.12	-0.24	-0.39	-0.05	0.02	0.42
Non Current Assets Total	-0.13	-0.7	-0.39	-0.04	-0.23	0.35	0.35	-0.48	-0.34		-0.18	-0.14	0.07	0.05	0.08	-0.34	-0.19	-0.19	-0.18	0.84	0.35	0.48	0.78	0.45	0.22	-0.07
Cash And Short Term Investments	0.98	0.33	-0.03	0.94	0.7	-0.86	-0.55	-0.04	0.87	-0.18		-0.29	0.62	0.34	0.63	0.56	0.21	0.6	0.99	-0.49	0.35	-0.13	-0.47	-0.06	-0.04	0.57
Net Receivables	-0.15	0.23	0.34	-0.33	0.04	0.26	-0.11	0.04	-0.22	-0.14	-0.29		-0.1	0.24	0.03	0.05	0.43	-0.12	-0.14	-0.13	0.18	0.09	-0.28	-0.24	0.13	0.08
Common Stock Shares Outstanding	0.7	-0.12	-0.11	0.48	0.59	-0.54	-0.84	-0.55	0.41	0.07	0.62	-0.1		0.81	0.98	0.86	0.39	0.89	0.67	-0.31	0.42	0.13	-0.4	0.43	0.08	0.86
Non Current Liabilities Total	0.46	-0.03	0.09	0.12	0.59	-0.31	-0.81	-0.63	0.23	0.05	0.34	0.24	0.81		0.87	0.75	0.71	0.68	0.44	-0.28	0.51	0.41	-0.45	0.21	0.28	0.83
Other Current Assets	0.73	-0.1	-0.03	0.47	0.62	-0.55	-0.84	-0.55	0.43	0.08	0.63	0.03	0.98	0.87		0.84	0.5	0.85	0.7	-0.31	0.47	0.24	-0.44	0.36	0.18	0.86
Other Stockholder Equity	0.63	0.23	0.21	0.34	0.71	-0.47	-0.98	-0.24	0.36	-0.34	0.56	0.05	0.86	0.75	0.84		0.57	0.86	0.62	-0.71	0.39	-0.04	-0.77	0.08	0.03	0.87
Total Liab	0.32	0.32	0.71	-0.1	0.64	-0.13	-0.6	-0.05	0.18	-0.19	0.21	0.43	0.39	0.71	0.5	0.57		0.4	0.33	-0.45	0.56	0.25	-0.56	-0.21	0.57	0.59
Property Plant And Equipment Gross	0.65	0.05	0.11	0.41	0.63	-0.68	-0.8	-0.35	0.52	-0.19	0.6	-0.12	0.89	0.68	0.85	0.86	0.4		0.63	-0.44	0.25	-0.2	-0.49	0.44	0.16	0.72
Total Current Assets	1.0	0.36	0.03	0.9	0.76	-0.84	-0.62	-0.08	0.86	-0.18	0.99	-0.14	0.67	0.44	0.7	0.62	0.33	0.63		-0.52	0.43	-0.08	-0.53	-0.08	0.02	0.65
Intangible Assets	-0.48	-0.72	-0.42	-0.3	-0.61	0.44	0.7	-0.33	-0.43	0.84	-0.49	-0.13	-0.31	-0.28	-0.31	-0.71	-0.45	-0.44	-0.52		-0.13	0.32	0.97	0.51	0.17	-0.48
Non Currrent Assets Other	0.45	0.24	0.23	0.24	0.69	-0.06	-0.42	-0.22	0.12	0.35	0.35	0.18	0.42	0.51	0.47	0.39	0.56	0.25	0.43	-0.13		0.2	-0.19	-0.25	0.32	0.54
Short Term Investments	-0.06	-0.5	-0.15	-0.15	-0.05	0.29	-0.05	-0.51	-0.24	0.48	-0.13	0.09	0.13	0.41	0.24	-0.04	0.25	-0.2	-0.08	0.32	0.2		0.2	0.0	0.23	0.22
Short Term Debt	-0.49	-0.67	-0.41	-0.25	-0.63	0.41	0.79	-0.2	-0.39	0.78	-0.47	-0.28	-0.4	-0.45	-0.44	-0.77	-0.56	-0.49	-0.53	0.97	-0.19	0.2		0.45	0.13	-0.59
Other Assets	-0.03	-0.74	-0.32	-0.03	-0.29	-0.12	0.01	-0.49	-0.05	0.45	-0.06	-0.24	0.43	0.21	0.36	0.08	-0.21	0.44	-0.08	0.51	-0.25	0.0	0.45		0.18	0.06
Other Current Liab	0.04	-0.17	0.6	-0.23	0.16	-0.03	0.01	-0.09	0.02	0.22	-0.04	0.13	0.08	0.28	0.18	0.03	0.57	0.16	0.02	0.17	0.32	0.23	0.13	0.18		0.01
Common Stock	0.65	0.19	-0.01	0.42	0.77	-0.41	-0.93	-0.52	0.42	-0.07	0.57	0.08	0.86	0.83	0.86	0.87	0.59	0.72	0.65	-0.48	0.54	0.22	-0.59	0.06	0.01

Click cells to compare fundamentals

Oncolytics Biotech Account Relationship Matchups

Oncolytics Biotech balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	19.7M	34.3M	45.9M	37.3M	38.8M	30.5M
Total Current Liabilities	12.9M	2.7M	2.7M	3.9M	4.2M	3.9M
Total Stockholder Equity	(107.9K)	24.8M	36.1M	26.5M	27.6M	17.8M
Property Plant And Equipment Net	727.5K	609.1K	976.3K	652K	647K	460.6K
Net Debt	(13.6M)	(30.8M)	(40.6M)	(11.3M)	(34.5M)	(32.8M)
Retained Earnings	(344.6M)	(367.1M)	(393.4M)	(418.3M)	(446.0M)	(423.7M)
Accounts Payable	3.2M	1.8K	594K	2.3M	1.1M	1.0M
Cash	14.1M	31.2M	41.3M	11.7M	34.9M	19.4M
Non Current Assets Total	727.5K	609.1K	976.3K	1.7M	647K	614.7K
Cash And Short Term Investments	14.1M	31.2M	41.3M	32.1M	34.9M	26.6M
Net Receivables	2.1M	89.7K	866.1K	521K	15K	14.3K
Common Stock Shares Outstanding	22.1M	40.3M	53.5M	58.0M	67.6M	71.0M
Liabilities And Stockholders Equity	19.7M	34.3M	45.9M	37.3M	38.8M	30.5M
Non Current Liabilities Total	6.9M	6.9M	7.1M	6.9M	7.0M	7.4M
Other Current Assets	1.5M	2.4M	2.8M	3.0M	3.2M	3.4M
Other Stockholder Equity	33.0M	31.0M	34.2M	40.1M	42.1M	42.9M
Total Liab	19.8M	9.6M	9.8M	10.8M	11.3M	6.0M
Property Plant And Equipment Gross	727.5K	609.1K	976.3K	652K	1.3M	1.4M
Total Current Assets	18.9M	33.7M	44.9M	35.7M	38.2M	28.0M
Accumulated Other Comprehensive Income	464.1K	400.2K	387.7K	662K	544K	516.8K
Short Term Investments	13.1M	30.4M	1.4M	20.5M	3.4M	3.2M
Short Term Debt	339.8K	248.9K	294K	216K	133K	126.4K
Other Current Liab	12.5M	2.5M	1.8M	1.5M	3.0M	3.2M
Common Stock	311.1M	356.8M	391.3M	404.0M	430.9M	310.7M
Common Stock Total Equity	271.7M	285.2M	311.1M	356.8M	410.3M	294.9M
Net Tangible Assets	(107.9K)	24.8M	36.1M	26.5M	30.5M	19.0M
Property Plant Equipment	727.5K	609.1K	976.3K	652K	749.8K	610.4K
Capital Surpluse	33.0M	34.6M	37.8M	40.1M	46.1M	35.9M
Long Term Debt Total	166.4K	153.2K	361.1K	157K	180.6K	131.6K
Cash And Equivalents	1.1M	858.0K	1.4M	11.7M	13.4M	14.1M
Current Deferred Revenue	(3.2K)	(1.8K)	(594K)	(1.1M)	(973.8K)	(925.1K)
Net Invested Capital	(107.9K)	24.8M	36.1M	26.5M	27.6M	20.3M
Net Working Capital	6.1M	31.0M	42.2M	31.7M	33.9M	26.6M
Capital Stock	311.1M	356.8M	391.3M	404.0M	430.9M	399.6M

Pair Trading with Oncolytics Biotech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oncolytics Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oncolytics Biotech will appreciate offsetting losses from the drop in the long position's value.

Moving against Oncolytics Stock

0.36

THRM

Therma Bright

Pair Corr

The ability to find closely correlated positions to Oncolytics Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oncolytics Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oncolytics Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oncolytics Biotech to buy it.

The correlation of Oncolytics Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oncolytics Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oncolytics Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Oncolytics Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Oncolytics Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oncolytics Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oncolytics Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oncolytics Biotech Stock:

How To Invest In Oncolytics

Details

Is Oncolytics Stock a good investment?

Details

What is Oncolytics Biotech's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide.

You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Please note, there is a significant difference between Oncolytics Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncolytics Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncolytics Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Oncolytics Historical Balance Sheet

About Oncolytics Balance Sheet Analysis

Oncolytics Biotech Balance Sheet Chart

Total Assets

Total Current Liabilities

Property Plant And Equipment Net

Net Tangible Assets

Oncolytics Biotech balance sheet Correlations

Oncolytics Biotech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Oncolytics Biotech balance sheet Accounts

Pair Trading with Oncolytics Biotech

Moving against Oncolytics Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 0.99	Cash And Short Term Investments
Cash And Short Term Investments	+ 0.98	Total Assets
Other Current Assets	+ 0.98	Common Stock Shares Outstanding
Short Term Debt	+ 0.97	Intangible Assets
Cash And Short Term Investments	+ 0.94	Total Stockholder Equity

Other Stockholder Equity	- 0.98	Retained Earnings
Cash	- 0.95	Net Debt
Common Stock	- 0.93	Retained Earnings
Cash And Short Term Investments	- 0.86	Net Debt
Other Current Assets	- 0.84	Retained Earnings
Common Stock Shares Outstanding	- 0.84	Retained Earnings